Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders (Q39453608)

12 September 2017

1 reference

title

Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders (English)

1 reference

12 September 2017

1 reference

Langtry HD

1

1 reference

PubMed ID

9279507

12 September 2017

Wilde MI

series ordinal

2

1 reference

12 September 2017

1 September 1997

1 reference

12 September 2017

1 reference

12 September 2017

54

1 reference

12 September 2017

3

1 reference

12 September 2017

473-500

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199754030-00010

12 September 2017

0 references

cites work

Therapeutic effects of lansoprazole on peptic ulcers in elderly patients

1 reference

12 December 2020

Efficacy of lansoprazole and amoxicillin in eradicating Helicobacter pylori: evaluation using 13C-UBT and Monoclonal H. pylori antibody testing

1 reference

12 December 2020

Lansoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion

1 reference

12 December 2020

Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy.

1 reference

12 December 2020

Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis

1 reference

12 December 2020

Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Autoradiographic demonstration of lansoprazole uptake sites in rat antrum and colon

1 reference

12 December 2020

Diagnosis and therapy of Helicobacter pylori infection. Guidelines of the German Society of Digestive and Metabolic Diseases

1 reference

12 December 2020

Effects of lansoprazole plus amoxycillin on the cure of Helicobacter pylori infection in Japanese peptic ulcer patients

1 reference

12 December 2020

Gastroesophageal reflux disease. The long and the short of therapeutic options

1 reference

12 December 2020

Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin

1 reference

12 December 2020

Dose-response effect of lansoprazole in patients with Zollinger-Ellison syndrome

1 reference

12 December 2020

A trial of lansoprazole in refractory gastric ulcer

1 reference

12 December 2020

Once or twice daily doses of proton pump inhibitor in treating Barrett's esophagus?

1 reference

12 December 2020

Proton pump inhibitors for Helicobacter pylori eradication in patients with peptic ulcer

1 reference

12 December 2020

Comparison of once daily doses of lansoprazole (15, 30, and 60 mg) and placebo in patients with gastric ulcer.

1 reference

12 December 2020

Triple therapy with lansoprazole, clarithromycin, and amoxicillin for the cure of Helicobacter pylori infection: a short report

1 reference

12 December 2020

A reliable cure for Helicobacter pylori infection?

1 reference

12 December 2020

Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease

1 reference

12 December 2020

Pharmacokinetic interaction between lansoprazole and theophylline

1 reference

12 December 2020

A comparison of lansoprazole, omeprazole, and ranitidine for reducing preoperative gastric secretion in adult patients undergoing elective surgery.

1 reference

12 December 2020

Inhibitory effects of intravenous lansoprazole on gastric acid hypersecretion in patients with postoperative stress.

1 reference

12 December 2020

Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter pylori infection

1 reference

12 December 2020

Treatment of erosive reflux esophagitis resistant to H2-receptor antagonist therapy. Lansoprazole, a new proton pump inhibitor

1 reference

12 December 2020

Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects

1 reference

12 December 2020

Lansoprazole versus famotidine in symptomatic reflux esophagitis: a randomized, multicenter study

1 reference

12 December 2020

Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group

1 reference

12 December 2020

Lansoprazole plus clarithromycin: evaluation of a new dual therapy for Helicobacter pylori eradication

1 reference

12 December 2020

Omeprazole and lansoprazole are not inducers of cytochrome P4501A2 under conventional therapeutic conditions

1 reference

12 December 2020

Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K(+)-ATPase inhibitor: a controlled, double-blind study. Lansoprazole Study Group

1 reference

12 December 2020

Lansoprazole in the prophylaxis of acid aspiration during elective surgery.

1 reference

12 December 2020

Eradication of Helicobacter pylori with lansoprazole and clarithromycin in gastric ulcer patients

1 reference

12 December 2020

Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology

1 reference

12 December 2020

[Anti-ulcer agents. Recommendations and medical references. Agence Nationale pour le Développement de l'Evaluation Médicale]

1 reference

12 December 2020

Lansoprazole: administration of the contents of a capsule dosage formulation through a nasogastric tube

1 reference

12 December 2020

Lansoprazole treatment of Helicobacter pylori-positive peptic ulcers

1 reference

12 December 2020

Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II, III and IVa (a Dutch multicentre trial). Dutch Study Group

1 reference

12 December 2020

Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin and clarithromycin

1 reference

12 December 2020

Lansoprazole does not affect the bioavailability of oral contraceptives

1 reference

12 December 2020

Zollinger-Ellison syndrome. Advances in treatment of gastric hypersecretion and the gastrinoma

1 reference

12 December 2020

The treatment of Helicobacter pylori infection in the management of peptic ulcer disease.

1 reference

12 December 2020

Lack of pharmacokinetic interaction after administration of lansoprazole or omeprazole with prednisone

1 reference

12 December 2020

Lansoprazole versus lansoprazole plus amoxicillin treatment for eradication of Helicobacter pylori in patients with gastric ulcer

1 reference

12 December 2020

Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis

1 reference

12 December 2020

Comparison of two lansoprazole-antibiotic combinations (amoxycillin or classical triple therapy) for treatment of H. pylori infection in duodenal ulcer patients

1 reference

12 December 2020

Suppressive action of lansoprazole on gastric acidity and its clinical effect in patients with gastric ulcers: comparison with famotidine

1 reference

12 December 2020

4-day lansoprazole quadruple therapy: a highly effective cure for Helicobacter pylori infection.

1 reference

12 December 2020

Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review

1 reference

12 December 2020

Comparison of lansoprazole (30 mg) and omeprazole (20 mg) in the treatment of duodenal ulcer. A multicenter double-blind comparative trial

1 reference

12 December 2020

How to achieve a near 100% cure rate for H. pylori infection in peptic ulcer patients. A personal viewpoint

1 reference

12 December 2020

Is short-term triple therapy with lansoprazole, clarithromycin, and metronidazole a definitive answer for Helicobacter pylori eradication?

1 reference

12 December 2020

The Effects of Lansoprazole on the Disposition of Antipyrine and Indocyanine Green in Normal Human Subjects

1 reference

12 December 2020

In-vitro activity of lansoprazole against Helicobacter pylori

1 reference

12 December 2020

Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial

1 reference

12 December 2020

Comparison of two low-dose one-week triple therapy regimens with and without metronidazole for cure of H. pylori infection

1 reference

12 December 2020

Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity

1 reference

12 December 2020

Eradication of Helicobacter pylori with lansoprazole, amoxicillin, and plaunotol in duodenal ulcer patients

1 reference

12 December 2020

[Lansoprazole versus ranitidine in the prevention of early recurrences of digestive hemorrhages from gastroduodenal ulcers. Randomized double-blind multicenter study]

1 reference

12 December 2020

Twenty-four-hour monitoring of intragastric acidity: comparison between lansoprazole 30mg and pantoprazole 40mg

1 reference

12 December 2020

Lansoprazole pharmacokinetics in subjects with various degrees of kidney function

1 reference

12 December 2020

Lansoprazole versus omeprazole in active duodenal ulcer. A double-blind, randomized, comparative study

1 reference

12 December 2020

Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group

1 reference

12 December 2020

The interaction of proton pump inhibitors with cytochromes P450.

1 reference

12 December 2020

One week treatment with omeprazole, clarithromycin and tinidazole or lansoprazole, amoxicillin and metronidazole for cure of Helicobacter pylori infection in duodenal ulcer patients

1 reference

12 December 2020

Prevention of recurrence of oesophageal stricture, a comparison of lansoprazole and high-dose ranitidine.

1 reference

12 December 2020

Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome

1 reference

12 December 2020

Clinical effect of proton pump inhibitors on reflux esophagitis

1 reference

12 December 2020

Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer. Lansoprazole Study Group

1 reference

12 December 2020

Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori

1 reference

12 December 2020

Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole

1 reference

12 December 2020

One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection.

1 reference

12 December 2020

Lansoprazole reduces preoperative gastric fluid acidity and volume in children.

1 reference

12 December 2020

Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus.

1 reference

12 December 2020

Dual therapy with lansoprazole and clarithromycin for eradication of Helicobacter pylori

1 reference

12 December 2020

Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders

1 reference

12 December 2020

Long-term acid control and proton pump inhibitors: interactions and safety issues in perspective

1 reference

12 December 2020

The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease

1 reference

12 December 2020

Safety of lansoprazole

1 reference

12 December 2020

Effects of lansoprazole on pharmacokinetics and metabolism of theophylline

1 reference

12 December 2020

Pharmacokinetics and absolute bioavailability of lansoprazole

1 reference

12 December 2020

A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection

1 reference

12 December 2020

Can eradication of Helicobacter pylori prevent gastric cancer? Gastrointestinal Physiology Working Group of Cayetano Heredia

1 reference

12 December 2020

Eradication of Helicobacter pylori with lansoprazole and clarithromycin.

1 reference

12 December 2020

Bedtime administration of lansoprazole does not modify its greater efficacy vs ranitidine in the acute and long-term treatment of duodenal ulcer. Results from a multicentre, randomised, double blind clinical trial.

1 reference

12 December 2020

Seven-day triple therapy with lansoprazole, clarithromycin, and metronidazole for the cure of Helicobacter pylori infection: a short report

1 reference

12 December 2020

A comparison of three doses of lansoprazole (15, 30 and 60 mg) and placebo in the treatment of duodenal ulcer. The Lansoprazole Study Group

1 reference

12 December 2020

Short report: treatment of gastric ulcer with lansoprazole or ranitidine: a multicentre clinical trial

1 reference

12 December 2020

Short-term low-dose triple therapy with lansoprazole plus amoxycillin and clarithromycin for Helicobacter pylori eradication.

1 reference

12 December 2020

Clinical efficacy of lansoprazole in eradication of Helicobacter pylori

1 reference

12 December 2020

Lansoprazole and amoxycillin: observations on the treatment of Helicobacter pylori infection

1 reference

12 December 2020

Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The Lansoprazole Maintenance Study Group.

1 reference

12 December 2020

[Erradicating treatment of Helicobacter pylori with lansoprazole and amoxicillin in duodenal ulcer patients]

1 reference

12 December 2020

Lansoprazole heals erosive reflux oesophagitis in patients with Barrett's oesophagus

1 reference

12 December 2020

Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer.

1 reference

12 December 2020

Determination of R(+)- and S(-)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans

1 reference

12 December 2020

Identification of the human P450 enzymes involved in lansoprazole metabolism.

1 reference

12 December 2020

Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders

1 reference

12 December 2020

Possible mechanism for the inhibition of gastric (H+ + K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749.

1 reference

12 December 2020

Peptic ulcer therapy with lansoprazole and Helicobacter pylori eradication

1 reference

12 December 2020

Lansoprazole: an alternative method of administration of a capsule dosage formulation

1 reference

12 December 2020

Effect of lansoprazole on peptic ulcers

1 reference

12 December 2020

Rapid healing of gastric ulcers with lansoprazole

1 reference

12 December 2020

Pharmacokinetics of lansoprazole in hemodialysis patients

1 reference

12 December 2020

A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group

1 reference

12 December 2020

Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition.

1 reference

12 December 2020

10.2165/00003495-199754030-00010

Identifiers

DOI

1 reference

PubMed ID

9279507

Dimensions Publication ID

12 September 2017

0 references

1 reference

PubMed ID

9279507